Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Upadacitinib - AbbVie

Next Previous
X
Search
Drug Profile

Upadacitinib - AbbVie

Alternative Names: ABT-494; RINVOQ; RINVOQ LQ; Upadacitinib extended release - Abbvie; Upadacitinib modified release - Abbvie; Upadacitinib prolonged release - Abbvie; Upadacitinib tartrate; Upadicitinib hemihydrate - Abbvie

Latest Information Update: 16 Jan 2025

Price :

$50 *

Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Abbott Laboratories
  • Developer AbbVie
  • Class Amides; Anti-inflammatories; Antipsoriatics; Antirheumatics; Fluorocarbons; Imidazoles; Pyrazines; Pyrroles; Pyrrolidines; Skin disorder therapies; Small molecules; Vascular disorder therapies
  • Mechanism of Action Janus kinase 1 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Ankylosing spondylitis; Atopic dermatitis; Crohn's disease; Juvenile rheumatoid arthritis; Psoriatic arthritis; Rheumatoid arthritis; Ulcerative colitis
  • Registered Non-radiographic axial spondyloarthritis
  • Preregistration Giant cell arteritis
  • Phase III Alopecia areata; Hidradenitis suppurativa; Systemic lupus erythematosus; Vasculitis; Vitiligo

Most Recent Events

  • 22 Dec 2024 Phase-III clinical trials in Atopic dermatitis (In children) in Japan (PO) (NCT06701331)
  • 22 Nov 2024 AbbVie plans a phase III trial for Atopic dermatitis (In children) in December 2024 (NCT06701331)
  • 30 Sep 2024 Abbvie completes the phase-III SELECT-PsA 2 trial in Psoriatic arthritis (Treatment-experienced) in USA, Australia, Belgium, Belgium, Canada, Brazil, Chile, Czech Republic, Czech Republic, France, Greece, Hungary, Italy, Japan, South Korea, Netherlands, New Zealand, Portugal, Spain, United Kingdom (PO) (NCT03104374)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top